Psilocybin and psychedelic research

Psychedelics are drugs that strongly change how a person sees, hears, thinks and feels for several hours. Researchers are testing a few of them, such as psilocybin (the active substance in "magic mushrooms") and MDMA, as possible treatments for depression and PTSD.

This page explains where the research stands as of October 2026. It covers what the FDA has and has not decided, the real risks, and how the state programs in Oregon and Colorado work. It also explains why trying these drugs on your own is not safe.

What psychedelics are

Psilocybin comes from certain mushrooms. The body turns it into psilocin, which acts a lot like LSD.¹ The FDA calls psilocybin and LSD "classic psychedelics." MDMA belongs to a different group, sometimes called empathogens. These are drugs that can increase feelings of closeness to others.⁴

In research, these drugs are not handed out like a daily pill. A person usually takes one or a few doses in a calm room while trained staff stay with them the whole time. The FDA's 2026 guidance for studies calls for two monitors during the entire session, with a doctor nearby.⁴ Talk sessions before and after are usually part of the plan.

Experts say your mindset ("set") and surroundings ("setting") shape the experience. A trained therapist should manage both, because they are central to safety.¹

Ketamine and esketamine are different. Esketamine (Spravato) is already FDA-approved for hard-to-treat depression. See our page on ketamine and esketamine.

What the research shows so far

Psilocybin for depression

A 2023 review of five studies with 215 people found that psilocybin, given with mental health support, eased depression for up to about five weeks. Longer benefits are possible but not proven.¹ One 2023 study of 104 people found a single dose helped within about a week, and the benefit lasted six weeks.¹

But psilocybin was not a clear winner every time. In a 2021 study of 59 people, it did no better than escitalopram, a common antidepressant, given with talk therapy.¹

What this means for you. Some people in these studies felt much better for weeks. But the studies were small, and most followed people for only a short time. It is also hard to keep a study fair. Most people can tell if they got the real drug, and that can make results look better than they are.^1,4

That is why the VA and Department of Defense depression guideline strongly advises against using psilocybin, MDMA or cannabis for depression outside a research setting. The reason it gives is that too little is known about safety and benefit.⁸

MDMA for PTSD

MDMA is the drug sold on the street as ecstasy or molly. In MDMA-assisted therapy, a person takes it during long, supervised sessions with therapists.

In a 2023 study of 104 adults with PTSD, everyone got therapy. Half also got MDMA and half got a placebo (a look-alike with no drug).⁷ At the end, about 7 in 10 people in the MDMA group (71%) no longer met the criteria for PTSD. In the placebo group, about 5 in 10 (48%) did.⁷ Blood pressure and pulse went up during dosing sessions. Muscle tightness, nausea, sweating and less appetite were more common with MDMA.⁷

The 2023 VA/DoD PTSD guideline did not recommend for or against MDMA, because the evidence was low quality. Psilocybin studies for PTSD were too weak to be included in its review.⁹ For proven PTSD treatments, see trauma-focused therapies and medicines for PTSD.

Other uses being studied

A 2022 study of 93 people with alcohol use disorder found fewer heavy drinking days with psilocybin-assisted therapy over 32 weeks. Most people guessed which treatment they got, and the long-term effect is unknown.¹ Small studies have also looked at anxiety and distress in people with serious illness.¹ Researchers are testing related drugs too, such as methylone for PTSD and noribogaine for alcohol use disorder.³

No psychedelic is approved to treat dementia or memory loss.

Where the FDA stands in October 2026

The MDMA decision. In June 2024, an FDA panel of outside experts met about MDMA for PTSD. Nine of 11 voted that the data did not show it works. Ten of 11 voted that the benefits did not outweigh the risks.⁵ The panel worried that people could tell whether they got MDMA. It also raised concerns about heart monitoring, misuse, and how long benefits last.⁵ In August 2024, the FDA asked for more research on those points.⁶ In August 2026, the company, now called Resilient Pharmaceuticals, sent a new application. It relies on the older studies and does not include a new large trial.⁶

Steps that speed up review. In April 2026, the President issued an order asking health agencies to speed up access to treatments for serious mental illness. The FDA then gave priority vouchers to companies studying psilocybin for two kinds of depression and methylone for PTSD.³ In July 2026, the FDA finalized its guidance on how psychedelic studies should be run.⁴ It also set a public hearing for September 14, 2026, to gather ideas on how these drugs might be used safely in the future, if approved.²

What these steps do not mean. The FDA says that vouchers and "breakthrough" status are not a finding that a drug is safe or that it works. They do not replace approval.² A drug could still be turned down. For MDMA, the FDA had proposed a special safety program, called a REMS (Risk Evaluation and Mitigation Strategy), with extra rules for its use.⁵ Any approved psychedelic would likely come with strict safety rules too.

The risks are real

Psilocybin can raise blood pressure and heart rate. It can also cause headache, nausea, dizziness, tiredness and poor sleep.¹ Mental effects can include anxiety, paranoia (feeling that others want to harm you) and hallucinations. Some people have a frightening "bad trip" full of fear, confusion or panic. In some people, psychosis can last.¹

Other risks to know about:

• Poisoning. Some poisonous wild mushrooms look like psilocybin mushrooms. Very high doses can be deadly.¹
• Hidden drugs. Street products may contain other drugs, including fentanyl.¹
• Unclear effects of microdosing. Taking tiny, regular amounts ("microdosing") has not been shown to be safe or helpful. Reported effects include poor sleep, more anxiety, low mood and trouble focusing.¹
• Poor judgment for hours. The FDA notes that these drugs can affect judgment and decisions, and people may stay vulnerable for hours or longer.⁴ Do not drive after a session. Oregon requires a ride plan before any session.¹⁰
• Drug interactions. Some antidepressants may weaken the effects. Lithium and some other medicines may make the effects stronger.⁴ Combining MAOI antidepressants with MDMA-type drugs can cause a life-threatening rise in blood pressure.⁴ Oregon does not allow anyone who took lithium in the past 30 days to receive psilocybin services.¹⁰

Who should avoid psilocybin. NCCIH (part of the National Institutes of Health) says people with schizophrenia or other psychotic conditions, severe bipolar disorder or borderline personality disorder should not use it.¹ Oregon does not serve people with active psychosis or current thoughts of harming themselves or others.¹⁰

Extra cautions for older adults

Psilocybin raises blood pressure and heart rate for a while.¹ Many older adults live with high blood pressure, heart disease or past strokes, so this matters. The FDA asks drug makers to check closely for heart and blood pressure effects.⁴

Older adults also tend to take more medicines, which raises the chance of a harmful mix. Confusion, dizziness and a wobbly walk during a session can lead to falls. People living with dementia may be more easily frightened or confused by strong changes in what they see and feel.

If you are curious about these drugs, start with your own doctor and bring a full list of your medicines.

State psilocybin programs: Oregon and Colorado

Two states now let adults use psilocybin with a trained guide under state rules. These programs are not FDA-approved medical treatment, and psilocybin is still illegal under federal law.¹

Facilitators are not doctors or therapists. In Oregon, facilitators can turn down anyone for any reason.¹⁰ No diagnosis is needed, and the sessions are not medical treatment. Your answers on a screening form can make you ineligible or mean you need a support person with you.¹⁰

Be careful of scams. Colorado has warned the public about fraud and scams involving natural medicine.¹³ Use the state's license lookup tools to check a center or facilitator before you pay.^11,13

Some other states have passed or proposed their own laws, and the rules differ from place to place.¹ Federal law still applies everywhere.

How to take part in research safely

If you want to explore these treatments, a clinical trial is the safest way. Trials screen people carefully, watch for side effects and follow up afterward.

1. Talk with your doctor or psychiatrist first. Ask whether a trial makes sense for you.
2. Search ClinicalTrials.gov for "psilocybin" or "MDMA" plus your condition. Only trust studies listed there.
3. Ask the study team who runs the trial, what risks they expect and what happens if you have a bad reaction.
4. Be wary of anyone who charges a large fee to "join a study."
5. Read our guide to joining a clinical trial. Most of its tips apply to any trial.

Treatments that work now

You do not need to wait for psychedelics to get better. For depression, talk therapy, antidepressants and other options help many people. If several treatments have not worked, ask about options for depression that doesn't get better, including esketamine, TMS and ECT. See also brain stimulation and how to find a therapist.

Questions to ask your doctor

Is a psychedelic study right for me?

• Do my health problems or medicines make it unsafe for me?
• Have I tried the proven treatments for my condition?
• Can you help me find a trustworthy study?

I've read about state programs. What should I know?

• Could psilocybin interact with my medicines?
• Is my heart and blood pressure healthy enough?
• What should I do if I feel worse afterward?

Education only. This page is general information written from the sources listed. It is not medical, legal or financial advice and does not replace a doctor, therapist or lawyer who knows your situation. How we write and check pages.